公开(公告)号：US11452736B2

公开(公告)日：2022-09-27

申请号：US16768333

申请日：2018-11-30

Applicant: GLYCOM A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  A23L33/21 ,  A23L33/00 ,  A61P1/00

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.

公开(公告)号：US20220185837A1

公开(公告)日：2022-06-16

申请号：US17653819

申请日：2022-03-07

Applicant: GLYCOM A/S

Inventor： Martin MATWIEJUK ,  Pierre CHASSAGNE ,  Markus JONDELIUS HEDEROS

IPC: C07H1/06 ,  C07H13/04 ,  A61K31/702 ,  A23L33/125 ,  A23L33/00

Abstract: The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.

公开(公告)号：US11291677B2

公开(公告)日：2022-04-05

申请号：US16613082

申请日：2018-05-09

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  A61P1/00 ,  A61K9/00 ,  A61K35/745

Abstract: The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.

公开(公告)号：US20220056065A1

公开(公告)日：2022-02-24

申请号：US17415274

申请日：2019-12-19

Applicant: Glycom A/S

Inventor： Nikolay KHANZHIN ,  Markus JONDELIUS HEDEROS ,  Pierre CHASSAGNE

IPC: C07H1/06 ,  C12P19/26 ,  B01D15/12

Abstract: The invention relates to a method for the separation of two hydrophilic neutral oligosaccharides from each other with a chromatography on a bromine functionalized polystyrene cross-linked with divinylbenzene (BPS-DVB) stationary medium.

公开(公告)号：US20210393657A1

公开(公告)日：2021-12-23

申请号：US17239889

申请日：2021-04-26

Applicant: GLYCOM A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61K35/745 ,  A61K9/20 ,  A61K9/48 ,  A23L33/21 ,  A23L33/135

Abstract: A method for reducing the likelihood of a non-infant human experiencing a cardiovascular disease (CVD) associated with hypercholesterolemia, hypertension, or a metabolic disorder such as type II diabetes and/or insulin resistance. Various examples of the method include selecting an amount of one to five human milk oligosaccharides (HMOs) selected from the fucosylated HMOs 2′-fucosyllatcose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), and lacto-N-fucopentaose I (LNFP-I) and the non-fucosylated neutral HMOs lacto-N-tetraose and lacto-N-neotetraose that is effective for increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human; increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing serum levels of low-density lipoprotein (LDL) cholesterol and/or increasing GLP-1 or reducing hypertension in the non-infant human by administering the selected amount of the selected HMOs during an initial treatment phase.

公开(公告)号：US20210386766A1

公开(公告)日：2021-12-16

申请号：US17353749

申请日：2021-06-21

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61K31/7016 ,  A61P1/00

Abstract: This disclosure relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.

公开(公告)号：US20210308158A1

公开(公告)日：2021-10-07

申请号：US17341039

申请日：2021-06-07

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23L33/21 ,  A23C9/20

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof

公开(公告)号：US11026959B2

公开(公告)日：2021-06-08

申请号：US15897099

申请日：2018-02-14

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/70 ,  A61K31/7012 ,  A61K31/7004 ,  A23L33/21 ,  A61K31/702 ,  A61P1/04 ,  A23C9/20

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT).

公开(公告)号：US20210052615A1

公开(公告)日：2021-02-25

申请号：US17093337

申请日：2020-11-09

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

公开(公告)号：US10881674B2

公开(公告)日：2021-01-05

申请号：US15183404

申请日：2016-06-15

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Emma Elison

IPC: A61K31/702 ,  A61K9/00 ,  A61K9/20

Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).